- Home
- CEV vs NSRX Comparison
CEV vs NSRX Comparison
Compare CEV & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | NSRX |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 63.4M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | CEV | NSRX |
|---|---|---|
| Price | $10.32 | $5.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 19.6K | 4.8K |
| Earning Date | 01-01-0001 | 03-20-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.83 | $5.42 |
| 52 Week High | $10.91 | $9.99 |
Technical Indicators
Market Signals| Indicator | CEV | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 36.49 |
| Support Level | $10.11 | $5.50 |
| Resistance Level | $10.21 | $7.70 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 83.87 | 3.60 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.